open access

Vol 15, No 2 (2019)
Research paper
Published online: 2019-05-17
Get Citation

Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

Beata Hryciuk, Bartosz Szymanowski, Michał Bieńkowski, Adrian Perdyan, Aleksandra Korwat, Kamil Winnik, Barbara Radecka, Jolanta Żok, Natalia Cichowska, Katarzyna Sosińska-Mielcarek, Rafał Pęksa, Renata Duchnowska
DOI: 10.5603/OCP.2019.0011
·
Oncol Clin Pract 2019;15(2):85-88.

open access

Vol 15, No 2 (2019)
ORIGINAL ARTICLE
Published online: 2019-05-17

Abstract

Introduction. Tissue microarray (TMA) technique has been widely used, especially in immunohistochemical assays of new prognostic and predictive markers. The main objections raised by its opponents are the small amount of sampled material and the associated risk of inadequate assessment of analysed expression, resulting from the potential heterogeneity of tumour tissue. Material and methods. This study evaluated the compatibility of biomarker expression in two independent tissue cores, 1.5 mm in diameter, obtained by TMA technique from patients with gallbladder cancer (ERb, cytoPgR, HER2, CTGF) and ovarian cancer (PTEN, BCL2, PIK3CA, IGF1R). Comparison of the expression of individual biomarkers between cores was performed using the intraclass correlation coefficient (ICC), assuming a kappa < 0.4 as a weak, ≥ 0.4 as sufficient, ≥ 0.6 as good, and ≥ 0.75 as optimal correlation, and Kendall’s tau test — ICC package. Results. Evaluation of biomarker expression in the primary tumour was performed in 60 patients with gallbladder cancer and in 64 patients with high-grade serous ovarian cancer. Additionally, in patients with follicular cancer, the expression of the tested markers was assessed in the epithelium free from neoplastic malignancy. In both tumours, a good or sufficient level of homogeneity was observed in the expression of the analysed biomarkers between tissue cores. The correlation coefficient for the expression of individual markers in gallbladder cancer and adhering healthy tissue was: 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for ERb, 0.44 (95% CI: 0.23–0.61)/0.77 (95% CI: 0.61–0.87) for cytoPgR, 0.77 (95% CI: 0.65–0.85)/0.66 (95% CI: 0.44–0.80) for HER2, and 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for CTGF. In patients with ovarian cancer, the correlation coefficient within the primary tumour was 0.82 (95% CI: 0.71–0.89) for PTEN, 0.84 (95% CI: 0.75–0.90) for BCL2, 0.71 (95% CI: 0.56–0.81) for PIK3CA, and 0.77 (95% CI: 0.65–0.85) for IGF1R. Conclusions. Tissue microarray technique allows reliable assessment of the expression of tissue biomarkers within the primary tumour of gallbladder cancer and ovarian cancer.

Abstract

Introduction. Tissue microarray (TMA) technique has been widely used, especially in immunohistochemical assays of new prognostic and predictive markers. The main objections raised by its opponents are the small amount of sampled material and the associated risk of inadequate assessment of analysed expression, resulting from the potential heterogeneity of tumour tissue. Material and methods. This study evaluated the compatibility of biomarker expression in two independent tissue cores, 1.5 mm in diameter, obtained by TMA technique from patients with gallbladder cancer (ERb, cytoPgR, HER2, CTGF) and ovarian cancer (PTEN, BCL2, PIK3CA, IGF1R). Comparison of the expression of individual biomarkers between cores was performed using the intraclass correlation coefficient (ICC), assuming a kappa < 0.4 as a weak, ≥ 0.4 as sufficient, ≥ 0.6 as good, and ≥ 0.75 as optimal correlation, and Kendall’s tau test — ICC package. Results. Evaluation of biomarker expression in the primary tumour was performed in 60 patients with gallbladder cancer and in 64 patients with high-grade serous ovarian cancer. Additionally, in patients with follicular cancer, the expression of the tested markers was assessed in the epithelium free from neoplastic malignancy. In both tumours, a good or sufficient level of homogeneity was observed in the expression of the analysed biomarkers between tissue cores. The correlation coefficient for the expression of individual markers in gallbladder cancer and adhering healthy tissue was: 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for ERb, 0.44 (95% CI: 0.23–0.61)/0.77 (95% CI: 0.61–0.87) for cytoPgR, 0.77 (95% CI: 0.65–0.85)/0.66 (95% CI: 0.44–0.80) for HER2, and 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for CTGF. In patients with ovarian cancer, the correlation coefficient within the primary tumour was 0.82 (95% CI: 0.71–0.89) for PTEN, 0.84 (95% CI: 0.75–0.90) for BCL2, 0.71 (95% CI: 0.56–0.81) for PIK3CA, and 0.77 (95% CI: 0.65–0.85) for IGF1R. Conclusions. Tissue microarray technique allows reliable assessment of the expression of tissue biomarkers within the primary tumour of gallbladder cancer and ovarian cancer.
Get Citation

Keywords

tissue microarrays; biomarkers; gallbladder cancer; ovarian cancer

About this article
Title

Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 2 (2019)

Article type

Research paper

Pages

85-88

Published online

2019-05-17

DOI

10.5603/OCP.2019.0011

Bibliographic record

Oncol Clin Pract 2019;15(2):85-88.

Keywords

tissue microarrays
biomarkers
gallbladder cancer
ovarian cancer

Authors

Beata Hryciuk
Bartosz Szymanowski
Michał Bieńkowski
Adrian Perdyan
Aleksandra Korwat
Kamil Winnik
Barbara Radecka
Jolanta Żok
Natalia Cichowska
Katarzyna Sosińska-Mielcarek
Rafał Pęksa
Renata Duchnowska

References (19)
  1. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest. 1986; 55(2): 244–248.
  2. Hewitt SM. Tissue microarrays as a tool in the discovery and validation of predictive biomarkers. Methods Mol Biol. 2012; 823: 201–214.
  3. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7): 844–847.
  4. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008; 26(34): 5630–5637.
  5. Team RC (2015) R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, 2015). http://www.R-project.org.
  6. Wolak ME, Fairbairn DJ, Paulsen YR. Guidelines for estimating repeatability. Methods in Ecology and Evolution. 2012; 3: 129–137.
  7. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10): 883–892.
  8. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46(3): 225–233.
  9. Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med. 2014; 276(1): 41–51.
  10. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000; 80(12): 1943–1949.
  11. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol. 2003; 16(1): 79–84.
  12. Fonseca FP, de Andrade BA, Rangel AL, et al. Tissue microarray is a reliable method for immunohistochemical analysis of pleomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117(1): 81–88.
  13. Khouja MH, Baekelandt M, Sarab A, et al. Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett. 2010; 1(5): 827–831.
  14. Griffin MC, Robinson RA, Trask DK. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol. 2003; 16(12): 1181–1188.
  15. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch. 2003; 443(2): 115–121.
  16. Gomaa W, Ke Y, Fujii H, et al. Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch. 2005; 447(4): 701–709.
  17. Su Y, Shrubsole MJ, Ness RM, et al. Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2006; 15(9): 1719–1726.
  18. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004; 17(7): 790–797.
  19. Leversha MA, Fielding P, Watson S, et al. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol. 2003; 200(5): 610–619.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl